In order to improve leukemia-free survival (LFS) without the treatment-related morbidity of allogeneic bone marrow transplantation or multiple prolonged cycles of consolidation chemotherapy, we evaluated the long-term outcome of autologous transplantation of peripheral blood progenitor cells (PBPCs) as postremission therapy in 129 patients aged 18-71 years (median 49 years) with newly diagnosed acute myelogenous leukemia (AML) in first complete remission (CR1). The median follow-up from remission for surviving patients was 62.2 months (range 3.7-127.9 months). A total of 57 patients were alive and leukemia free at the end of the study. The LFS and overall survival 5 years from remission were 40.2% (79.2%) and 41.4% (79.4%), respectively. The median LFS and overall survival are 17.3 and 23.3 months, respectively. Multivariate analysis identified age as the most significant predictor for both LFS and overall survival. Karyotype was also found to be predictive of outcome. Our results show that autologous transplantation of PBPC procured after a single cycle of highdose cytarabine-based consolidation chemotherapy for a population of adult patients with AML in CR1 produces a high likelihood of long-term LFS, offering a state of clinical minimal residual disease for the investigation of future therapeutic approaches.
Introduction
Modern dose-intensive consolidation chemotherapy for patients with acute myelogenous leukemia (AML) in first complete remission (CR1) produces a median remission duration of 10-18 months with 20-40% of patients surviving 5 years free of recurrence. 1, 2 In order to prolong leukemia-free survival (LFS), several postremission therapies have been evaluated including high-dose cytarabine (HIDAC)-based consolidation chemotherapy as well as myeloablative therapy and either allogeneic or autologous bone marrow transplantation (ABMT). 3, 4 Controlled clinical trials evaluating HIDAC alone or in combination with other agents have demonstrated prolonged LFS in 20-40% of patients treated with at least two courses. 5, 6 However, patients who derive benefit are younger, generally under the age of 60 years, and demonstrate more favorable disease characteristics. Allogeneic bone marrow transplantation (alloBMT) may be the most effective strategy to reduce the risk of relapse, but is associated with a high risk of treatment-related morbidity (TRM) and mortality, and is typically limited to patients aged 40 years or younger who have a histocompatible sibling donor. 7, 8 ABMT allows for the use of dose-intensive myeloablative preparative conditioning without the high TRM and mortality of allogeneic transplant, thus making ABMT an option available to a larger, unselected population of adults in CR1. 9 Previous studies have demonstrated that ABMT may achieve LFS rates of 30-50% for younger patients in CR1 with TRM of 10% or less. 10, 11 ABMT is also feasible in older AML patients with acceptable toxicity and relatively low TRM, thus broadening the application of this therapy to a larger population, including individuals with less favorable disease characteristics. 6, 11 However, limitations of ABMT include insufficient stem cell collection in some patients and slow hematopoietic reconstitution. 12 Autologous peripheral blood progenitor cells (PBPCs) may be a favorable alternative to bone marrow as a source of hematopoiesis allowing for faster engraftment with a reduced rate of infection or hemorrhagic complications. 13 Mobilization of PBPCs by the use of high-dose chemotherapy alone or in combination with growth factors, such as GM-CSF or G-CSF, may produce a sufficient number of progenitor cells to ensure early engraftment and serve as a means of reducing potential leukemia cell contamination. 14, 15 In order to assess the long-term outcome of myeloablative preparative conditioning without the high TRM and mortality of either allogeneic transplantation or purged autologous PBPCs, we evaluated the risk of relapse, LFS, and overall survival in 129 patients with AML in CR1 treated with high-dose chemoradiotherapy followed by the infusion of autologous PBPCs procured after high-dose consolidation chemotherapy as a form of in vivo purging. This large group of patients, followed over a 10-year period, represents a population of adult leukemia patients unrestricted on the basis of age or prognostic features. The effects of pretreatment characteristics including age, gender, history of preleukemia, and cytogenetics on treatment-related toxicity and LFS were also considered in this study with the longest follow-up yet reported using ABMT for AML in first remission.
Patients and methods
In total, 129 adult patients with newly diagnosed AML were enrolled in three sequential Acute Leukemia Protocol studies conducted by the UCLA School of Medicine from November 1992 to March 1, 2002 . Data were analyzed as of December 31, 2002 . These studies were approved by the University of California Los Angeles Office for the Protection of Research Subjects, and all patients provided written informed consent to participate.
The diagnosis of AML was made according to French -American-British criteria. 16 De novo AML was defined as no documented hematologic abnormality identified more than 2 months before diagnosis. 17 Preleukemia was defined as ineffective hematopoiesis documented more than 2 months before the diagnosis of AML by either an abnormal bone marrow evaluation or an otherwise unexplained peripheral blood cytopenia. 17, 18 Karyotype was interpreted as follows: (1) Patients received HIDAC-based consolidation treatment administered in a single course, which was started a median of 4 weeks after achieving CR. Consolidation chemotherapy consisted of HIDAC 2 g/m 2 administered as a 2-h i.v. infusion every 12 h for 4 days and mitoxantrone 10 mg/m 2 by i.v. bolus/ day for 3 days. Human recombinant G-CSF was administered at 5 mg/kg subcutaneously or i.v. or over 30 min beginning 1 day following completion of consolidation and continued until the completion of stem cell leukapharesis. A total of 41 patients received IL-2 both following consolidation chemotherapy and after autologous transplantation as previously described. 20 All the patients underwent autologous stem cell transplant after preparative conditioning with 11.25 Gy total body irradiation (TBI) given in five fractions over 2.5 days (before 1998) or eight fractions (after 1998) and cyclophosphamide, 60 mg/kg/day by i.v. infusion over 1 h daily for 2 days. All patients received mesna, 60 mg/kg/day by continuous i.v. infusion at the start of cyclophosphamide and continued for 24 h after the last dose. After completion of transplantation, no maintenance cytotoxic therapy or other antileukemia therapy was administered until relapse.
Progenitor cell collection and processing
Progenitor cell apheresis was begun after an absolute neutrophil count 41500 mm À3 was achieved during the recovery phase from consolidation therapy. Continuous-flow leukapheresis was performed daily on weekdays with Cobe Spectra (Cobe, Lakewood, CO, USA) until a total nucleated cell count of X3 Â 10 8 /kg and/or CD34 cell count X1 Â 10 6 /kg was obtained. Blood volume processed per run was 10 l at a flow rate of 50-70 ml/min. Platelet and erythrocyte fractions were reinfused continuously. The final apheresis product was centrifuged at 400 g, concentrated to 1 Â 10 8 cells/mm 3 , and cooled to 41C. Cytogenetics was analyzed on an aliquot of the leukapharesis collection in all patients undergoing progenitor cell procurement as previously described. 21 Cell counts were performed using a Coulter counter (Coulter Electronics, Hialeah, FL, USA). A target CD34-positive cell dose of 1.0 Â 10 6 /kg and/ or a mononuclear cell dose of 5.0 Â 10 8 /kg was used as collection end points. Samples were run on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) and after 1994, CD34-positive cells were defined with histogram analysis using the whole live-cell population. A back-up bone marrow was collected in one patient due to a low PBPC collection.
Supportive care for granulocytopenic patients consisted of reverse isolation in single rooms and treatment with oral nonabsorbable antibiotics, including nystatin and either norfloxacin or ciprofloxacin. Febrile granulocytopenic patients received imipenem or cefoperazone/sulbactam, or other broad-spectrum antibacterial antibiotics. Patients with documented or suspected fungal infections were treated with empiric amphotericin B or fluconazole. Random or single donor platelet transfusions were administered to maintain a platelet count of X10 Â 10 9 /l. Erythrocytes were transfused to maintain a hematocrit X27%.
Statistical analysis
The date of diagnosis of AML and the date of remission were defined by the date of the diagnostic bone marrow studies. Patient survival and LFS from the time of remission were computed by the product-limit method of Kaplan and Meier. 22 Survival curves for univariate analysis of each potential predictor were compared using the log-rank test. Prognostic factors for LFS and overall survival were evaluated by multivariate analysis using Cox's proportional-hazard regression analysis. Analyses were performed using the SAS statistical package version 8. 23 P-values were two sided.
Results
In total, 129 patients with AML in CR1 undergoing autologous progenitor cell transplantation were entered into the study. The baseline characteristics of these patients at diagnosis are described in Table 1 . The median age was 49 years (range 18-71 years). A total of 72 patients had normal karyotypes, whereas 45 had abnormal cytogenetic studies. In all, 12 patients' karyotypes were not determined. In total, 34 patients had an antecedent hematologic disorder.
Survival
In all, 72 patients either died or had recurrence of disease by the termination of the study. A total of 57 persons were alive and leukemia free at the end of the study. 
Toxicity
Complications related to autologous PBPC transplant led to TRM in five patients. 20 Three patients succumbed to pulmonary complications, one to sepsis, and another to multiorgan failure.
Univariate survival analyses
Univariate analysis of all variables identified age, karyotype, and AML subtype as important predictors for LFS and overall survival from ABMT. The relative risk of relapse for patients greater than 60 years of age was 2.9 compared to patients under the age of 45 years ( Figure 3 and Table 2 ). Karyotype was also a statistically significant predictor of outcome. Patients with abnormal and unfavorable karyotypes had over 6.5 times the relative risk of relapse than patients with abnormal but favorable karyotypes ( Figure 4 and Table 2 ). Finally, AML subtype was also a significant predictor of outcome as displayed in Table 2 . The M5 subtype was found to be favorable for both LFS and overall survival. The two patients with biphenotypic disease experienced the worst outcome. The presence of a preleukemic phase was not an independent predictor of either LFS (P ¼ 0.6) or overall (P ¼ 0.7) patient survival. The use of IL-2 following consolidation chemotherapy and again after autologous transplantation in a subset of patients failed to affect significantly LFS (P ¼ 0.5) or overall (P ¼ 0.5) survival, as observed previously. 20 These results are summarized in Table 2 . 
Multivariate survival analysis
Multivariate analysis of all variables identified age and karyotype as important predictors for LFS and overall survival from ABMT. AML subtype failed to reach statistical significance for either parameter. The results of multivariate statistical analysis are summarized in Table 2 .
Discussion
In order to prevent relapse, a variety of postremission strategies have been used for the management of acute myeloid leukemia in adults, including multiple cycles of consolidation therapy or high-dose myeloablative conditioning and either allogeneic or autologous transplantation. 24, 25 The optimal form of postremission treatment, however, remains in dispute. Prolonged schedules of maintenance therapy have been replaced by more effective regimes including multiple cycles of HIDAC-based consolidation. 3, 26 This approach leads to demonstrable improvements in both LFS and overall survival for a defined population of younger patients with more favorable disease features. 17 Myeloablative therapy followed by alloBMT has been recommended for patients whose disease has less favorable characteristics but is generally reported for a limited population of younger patients with histocompatible sibling donors and favorable disease characteristics. Allogeneic transplantation carries a lower risk of leukemia recurrence, a higher relative risk of transplant-related morbidity, but the lack of a compatible donor and the older median age of patients with AML makes such a strategy of limited utility for the majority of patients. 27 In contrast, autologous bone marrow transplantation is a feasible postremission strategy available to a large population of patients and is associated with a comparatively lower risk of transplant-related morbidity, albeit at the expense of a greater risk of relapse.
In the present study, we analyzed the long-term outcome of autologous PBPC transplantation in a heterogeneous population of adult patients with AML in CR1. We previously demonstrated the feasibility and toxicity of such an approach based on an intent-to-treat analysis. In the present analysis, we determined the long-term outcome of a population of AML patients who underwent the autologous PBPC transplantation procedure and were followed for as long as a decade. We specifically sought to assess the impact of autologous PBPC transplantation and the stability of remission for a diverse population of adult patients in CR1, many with adverse pretreatment characteristics and many of whom who would not have been eligible for trials of allogeneic transplantation.
A total of 129 adults, median age 49 years, received autologous PBPC transplantation as postremission therapy. Survivors were followed for an average of 62.2 months, representing the longest reported follow-up for postremission autologous PBPC transplantation as treatment of AML. In this cohort, the median LFS and overall survival were 17.3 and 23.3 months, respectively, while actuarial LFS and overall survival were 40 and 41%, respectively, at 5 years. In fact, the last censored event occurred 44 months after remission, with response to ABMT stable thereafter. This study illustrates the ability to treat an unselected group of AML patients with a diverse range in age, karyotype, and leukemia subtype, and produce sustained LFS.
In a prospective, nonrandomized trial, investigators at our institution studied the long-term survival of 123 AML patients in CR1 who received HIDAC-based consolidation chemotherapy (2 g/m 2 every 12 h for 4 days with an anthracycline) to determine a point of reference against which other postremission therapies could be compared. After a median follow-up of 5 years, 27% remained in CR1. In a subsequent study, these results were compared with autologous stem cell transplantation (ASCT). In total, 59 consecutive patients under the age of 70 years (median age 45 years, range 18-69) were treated with HIDAC-mitoxantrone consolidation chemotherapy used as a method of in vivo purging for the purpose of autologous PBPC procurement and transplantation. The 3-year actuarial LFS was 42%, significantly better than that achieved for the historical control group receiving HIDAC consolidation alone. These results and others have led some to recommend ABMT or ASCT as a preferred postremission treatment for AML in adults. In an early study of autologous transplantation in AML, 52 adult patients (22 in CR1, 30 beyond CR1) received ABMT after conditioning with cyclophosphamide and TBI. TRM was low (6%) and sustained engraftment was achieved in all patients. Of note, when ABMT was performed in CR1, the investigators reported an actuarial LFS of 61% at 2.5 years, with an actuarial risk of relapse of 36%. 28 More recent nonrandomized studies have confirmed the utility of ABMT as CR1 therapy, with reported long-term remission in 45-75% of patients.
Four major randomized, prospective trials have compared the various postremission options for adults with AML. GIMEMA compared consolidation with HIDAC (500 mg/m 2 or 1 g/m 2 every 12 h for 6 days), alloBMT, and ABMT in 343 patients in CR1. Patients (age 10-45 years) were randomly assigned to receive either chemotherapy (n ¼ 104), ABMT (n ¼ 95), or alloBMT (n ¼ 144) on the basis of an available histocompatible donor. On an intent-to-treat basis, and after a median follow-up of 3.3 years, the 4-year LFS rate was 30% in the intensive chemotherapy group, 48% in the ABMT group, and 55% in the alloBMT group. 29 Overall survival from remission was not significantly different among the various treatment arms. The French GOELAM trial was a randomized comparison of HIDAC consolidation (n ¼ 78), unpurged ABMT (n ¼ 86), and alloBMT (n ¼ 73) for patients aged 15-50 years with AML in CR1. The median follow-up in this study was 5.1 years. The investigators found no difference in LFS rates (40, 44 , and 44%, respectively). 30 Further, when analysis was limited to patients who had received their assigned treatment courses, no difference in overall survival was observed. The MRC AML 10 trial used HIDAC to induce CR1 in 381 patients less than age 55 years with AML, then treated all patients with a single consolidation course of cytarabine (200 mg/m 2 /day for 5 days). Subsequently, patients were randomly assigned to receive either no further Leukemia-free survival by karyotype.
therapy or ABMT following conditioning with cyclophosphamide and TBI. The LFS and overall survival at 7 years was inferior in the group assigned to no further treatment (40 vs 53 and 45 vs 57%, respectively); however, the overall survival advantage identified in the ABMT group at 7 years failed to reach statistical significance. 31 Finally, the US Intergroup study randomly assigned 233 AML patients in CR1 to HIDAC alone (3 g/m 2 every 12 h for 6 days), ABMT or alloBMT and found an estimated LFS at 4 years of 35, 35 , and 43% on an intent-to-treat basis in each group, respectively. 32 The consolidation chemotherapy group enjoyed a statistically significant greater overall survival than the ABMT group, because patients assigned to consolidation were more likely to undergo salvage ABMT or alloBMT in second CR. A subsequent study confirmed that the most favorable results in ABMT for AML was achieved in patients with favorable cytogenetic profiles. 33 The results of these four randomized trials differ significantly, with two showing a benefit for ABMT and two showing no advantage. Furthermore, these studies are difficult to analyze and compare because of differences in trial protocols, poor compliance to the randomized treatment, age restrictions on patients entering the trials, and 'time censoring' of patients in the transplantation arms. Inconsistent patient populations, pretransplant regimens, and chemotherapy doses make it difficult to compare HIDAC chemotherapy with ABMT using the published data. Based on all the patients who entered these large trials (n ¼ 2687) and achieved remission, 1644 were assigned to autologous transplantation but only 815 received the assigned treatment. The analysis of data on an intent-to-treat basis despite a low compliance may under-represent the benefit of transplant (annotation article 34 ). Moreover, adverse effects of transplantation may be under-represented since those who received the assigned treatment were more likely to have a favorable response based on pretreatment prognostic factors. 35 The current study both complements the published data and adds new information to the body of knowledge surrounding ABMT in AML. We have shown previously that in a single institution study ABMT is feasible in a diverse patient population, with over 80% of patients receiving the intended treatment. 20 With a median follow-up for survivors of over 5 years, these results lend further support to the durability of the LFS achieved after ABMT. Taken in the context of the abovestated studies, our LFS and overall survival values are within the range of those experienced elsewhere, many of which have included four cycles of postremission therapy. A potential benefit of our approach is that by utilizing a single cycle of consolidation chemotherapy followed by autologous transplantation, one may avoid the significant risks anticipated with additional cycles of myelosuppressive consolidation therapy while maintaining favorable LFS rates. A strength of the current study is the inclusion of an older patient population that allows for analysis of the long-term outcome of this high-risk patient group that has been excluded from larger phase III trials, 29, 30 but has been evaluated retrospectively elsewhere. 36, 37 Our results indicate that the age at diagnosis is the most powerful predictor of outcome indicative of less favorable disease biology. The rate of relapse and mortality observed in older adults in the present study both support the concept of resistant disease biology associated with advanced patient age and further confirm that although ABMT is feasible in these patients, advanced age is an independent predictor of poor outcome. [38] [39] [40] Additionally, chromosomal abnormalities were found to be predictive of response to ASCT as has been reported recently elsewhere. 41 Interestingly, we found that the M5 subtype had a favorable prognosis in univariate analysis, yet this difference failed to carry significance in multivariate analysis. We interpret these results to indicate that the histological diagnosis of AML subtype was not predictive of disease biology when compared to the cytogenetic markers associated with this subtype (ie t(9;11)).
Since relapse of disease portends a poor outcome in AML, many current strategies have been aimed at lengthening overall survival by maintaining patients in first remission. 42 The data presented in this study represent the rates of LFS and overall survival in a diverse population of patients followed for over a 10-year period. The durability of ASCT after 3 years is documented herein, providing data that if a patient has not relapsed by 2-3 years he/she is unlikely to do so in the future. Further, in the setting of minimal residual disease, we present a body of data against which future novel approaches in maintenance therapy to prolong remission can be evaluated.
